Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorigerlimab plus docetaxel vs docetaxel in metastatic castration-resistant prostate cancer
2022-502982-49-00Phase 2Completed
- Sponsor
- MacroGenics
- Start
- Sep 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of lorigerlimab in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by MacroGenics. Primary endpoint: Radiographic progression-free survival (rPFS). Started Sep 2023; status: completed.
02
Drugs
lorigerlimab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2022-502982-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502982-49-00.